2 clinical trial of KB001, a Humaneered™, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations.

Lung Transplants Not Dangerous For Children With Cystic Fibrosis, After All - Experts Say Recent Study Was Seriously Flawed published Tue, 01 Apr 2008 01:00:00 PDT
Responding to a study published in the New England Journal of Medicine, which concluded that lung transplants were harmful for children with cystic fibrosis, articles published in the latest issue of Pediatric Transplantation refute the conclusions and argue that the highly influential research was severely flawed. According to two rebuttals published in the acclaimed journal, the conclusions of the study on post-transplant survival rates led by Theodore G.

Cystic Fibrosis In Mice published Tue, 01 Apr 2008 01:00:00 PDT
"Drug 'could aid cystic fibrosis'" is the headline on BBC News. The article says that "widely-used antidepressants could prevent infections which shorten the lives of many cystic fibrosis patients". The report is based on the findings from a study in mice which has shed further light on the biological processes involved in the changes to the lungs caused by the cystic fibrosis mutation. Lung infections are a major cause of death in people who have cystic fibrosis.

Cystic Fibrosis Foundation Announces Positive Early Results For Phase 2 Clinical Trial Of VX-770 - An Oral Compound To Treat CF published Fri, 28 Mar 2008 02:00:00 PDT
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Positive Early Results For Phase 2 Clinical Trial Of VX-770 For Cystic Fibrosis published Fri, 28 Mar 2008 01:00:00 PDT
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Cystic Fibrosis Foundation Announces Positive Early Results For Phase 2 Clinical Trial Of VX-770 - An Oral Compound To Treat CF published Fri, 28 Mar 2008 00:00:00 PDT
The Cystic Fibrosis Foundation announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.

Great Strides 2008 - Taking Steps To Cure Cystic Fibrosis, UK published Sat, 22 Mar 2008 01:00:00 PDT
Thousands of people will be taking steps to cure Cystic Fibrosis (CF) this year by taking part in a series of sponsored walks across the UK. Great Strides, sponsored by Solvay Healthcare, is a worldwide initiative to get people walking to help see off CF. The sponsored walks aim to raise funds to help the 8,000 people with CF in the UK look forward to a brighter future and a longer and better quality of life.

$5 Million Initiative To Enhance Care For Adults With Cystic Fibrosis published Wed, 19 Mar 2008 04:00:00 PDT
The Cystic Fibrosis Foundation has announced the launch of a new $5 million initiative to enhance care for the growing adult CF population. The initiative, called the Program for Adult Care Excellence (PACE), will expand the scope of adult care programs for people with cystic fibrosis.The number of adults with cystic fibrosis continues to increase as life expectancy for the disease continues to rise.

Research Promising For Cystic Fibrosis published Wed, 19 Mar 2008 01:00:00 PDT
New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS).

Cystic Fibrosis Development Better Understood published Mon, 10 Mar 2008 00:00:00 PDT
According to a report in the open-access journal PLoSComputational Biology, there is a specific molecularmechanism that could be responsible for the development of cysticfibrosis. The University of North Carolina at Chapel Hill researcherssuggest better understanding of the disease may help to develop newcorrective treatments.About 1 in 3000 children is born with cystic fibrosis (CF) in the USevery year.

First Step To Create Cystic Fibrosis Model Using Pigs published Fri, 07 Mar 2008 03:00:00 PDT
Cystic fibrosis is the most common genetic disease in Caucasians. The median lifespan for those with the disease is 36 years, and lung disease is the major cause of mortality. For years, scientists have studied cystic fibrosis using mice in which the cystic fibrosis gene was altered. However, mice do not develop lung disease like humans with cystic fibrosis.

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status For The Treatment Of Cystic Fibrosis published Wed, 05 Mar 2008 00:00:00 PDT
Mpex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. Levofloxacin is the active pharmaceutical ingredient in MP-376, the company's proprietary levofloxacin solution for inhalation.

Computer Simulations Point To Key Molecular Basis Of Cystic Fibrosis published Mon, 03 Mar 2008 02:00:00 PDT
Researchers from the University of North Carolina at Chapel Hill have identified a key molecular mechanism that may account for the development of cystic fibrosis, which about 1 in 3000 children are born with in the US every year. The findings, published February 29 in the open-access journal PLoS Computational Biology, add new knowledge to understanding the development of this disease and may also point the way to new corrective treatments.

Decline In Cystic Fibrosis Since Introduction Of Prenatal Carrier Screening published Thu, 28 Feb 2008 04:00:00 PDT
A brief report in the February 28, 2008, New England Journal of Medicine, led by researchers at the New England Newborn Screening Program (NENSP) of the University of Massachusetts Medical School (UMMS), indicates a declining incidence of a genetic disease, providing what may be the first demonstration of a link between two independent population-based screening programs.

Increased Cystic Fibrosis Severity And Deficiency In The Protein MBL2 Linked published Fri, 22 Feb 2008 03:00:00 PDT
Cystic fibrosis (CF), a hereditary disorder causing thick mucous production and frequent lung infections, is associated with a high mortality rate primarily due to lung failure. Although it is known that mutations in the CFTR gene cause the disease, variations in other genes between individuals with CF modify the severity of the disease.

Scorpion Peptide May Be Key To Secretory Diseases published Fri, 15 Feb 2008 00:00:00 PDT
Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases.In the December 28 issue of the Journal of Biological Chemistry, an international team of researchers describes how this novel peptide, called GaTx1, can control the movement of ions and water out of cells by interacting with a crucial chloride channel.

Genetic Cause Discovered For Bone Complications Due To Cystic Fibrosis published Fri, 08 Feb 2008 04:00:00 PDT
A recent study by Dr Christina Haston, a researcher of the McGill University Health Centre research Institute, sheds some new light on the bone problems that generally accompany cystic fibrosis. Dr Haston's study is pointing at genetics as contributing to this bone frailty, a finding which may have some implications in changing therapeutic practices. The article was published on February 1, 2008 in the American Journal of Respiratory and Critical Care Medicine.

)

Home l Contact l